DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
NOVA-22007 is an investigational drug.
There have been 24 clinical trials for NOVA-22007. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2012.
The most common disease conditions in clinical trials are Diabetes Mellitus, Insulin Resistance, and Disease. The leading clinical trial sponsors are Canadian Institutes of Health Research (CIHR), Canadian Network for Observational Drug Effect Studies, CNODES, and Drug Safety and Effectiveness Network, Canada.
There are six hundred and seventy-six US patents protecting this investigational drug and sixteen international patents.
Recent Clinical Trials for NOVA-22007
|Trial of Maintenance With Niraparib- Uterine Serous Carcinoma||Tesaro, Inc.||Phase 2|
|Trial of Maintenance With Niraparib- Uterine Serous Carcinoma||Northwell Health||Phase 2|
|Lisdexamfetamine for Adults With Bulimia Nervosa||Nova Scotia Health Authority||Phase 2|
Top disease conditions for NOVA-22007
Top clinical trial sponsors for NOVA-22007
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|NOVA-22007||Start Trial||Antidiabetic tricyclic compounds||Merck Sharp & Dohme (Rahway, NJ)||Start Trial|
|NOVA-22007||Start Trial||Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers||eFFECTOR Therapeutics, Inc. (San Diego, CA)||Start Trial|
|NOVA-22007||Start Trial||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Start Trial|
|NOVA-22007||Start Trial||Phosphonate compounds for treatment of medical disorders||Achillion Pharmaceuticals, Inc. (New Haven, CT)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|NOVA-22007||European Patent Office||3145915||2034-05-22||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|